Foretinib

CAT: 0804-HY-10338-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10338-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
CAS Number
[849217-64-7]
Product Name Alternative
XL880; GSK1363089; GSK089; EXEL-2880
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Met/HGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Foretinib.html
Concentration
10mM
Purity
99.59
Solubility
DMSO : 75 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=O
Molecular Formula
C34H34F2N4O6
Molecular Weight
632.65
Precautions
H302, H315, H319, H335
References & Citations
[1]Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69 (20), 8009-8016.|[2]Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011.|[3]Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res, 2010, 16 (13), 3507-3516.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
VEGFR1/Flt-1; VEGFR2/KDR/Flk-1

Related Products

CatalogName

Alternative Products

CatalogName
M16164-01Foretinib
T71187-01Foretinib phosphate
A2974-10Foretinib (GSK1363089)
A10998-25Foretinib 25mg
A10998-5Foretinib 5mg
A10998-50Foretinib 50mg

Popular Products